UP!

OMED $0.89

OMED target price
0.89
0
0
OncoMed Pharmaceuticals, Inc.
Type
Public
Traded as NASDAQ: OMED
Industry Pharmaceutical
Founded University of Michigan August 2004; 13 years ago (2004-08)
Founders
  • Michael Clarke
  • Max Wicha
Headquarters Redwood City, California, United States
Key people
  • Paul Hastings (CEO)
  • John Lewicki (R&D chief)
  • Chuck Alaimo (Operations director)
Revenue US$24,700,000 (2012)
Total assets US$207,600,000  (2016)
Number of employees
  • 83 (2013)
  • 47 (2007)
Website www.oncomed.com
Footnotes / references

OncoMed Pharmaceuticals, Inc. is a public American pharmaceutical development company headquartered in Redwood City, California. The company was founded in August 2004 by two University of Michigan investigators, Michael Clarke and Max S. Wicha. As of 2013, the company had 83 employees. OncoMed's drug discovery work focuses on developing "targeted antibodies against cancer stem cells". The cancer stem cell technologies on which OncoMed depends are licensed from the University of Michigan where they were developed by the founders of the company. OncoMed went public in 2013 and is listed on NASDAQ under the stock symbol OMED.

Oncomed was incorporated in Delaware in 2004.

In 2007, Oncomed consolidated its operations located in Mountain View and Palo Alto, California onto the single headquarters campus at Seaport Centre in Redwood City. One of the buildings on the new campus was the former home of NeXT.

In 2012, OncoMed sponsored the USAN nonproprietary name vantictumab for a human IgG2 anti-Frizzled antibody, an anti-cancer therapeutic. In the same year, the company sponsored the USAN name demcizumab for a human IgG2 anti-DLL4 antibody, also an anti-cancer therapeutic.

In 2014, OncoMed entered into an anti-cancer stem cell therapeutic development agreement with Celgene encompassing demcizumab and five other biologics from OncoMed's pipeline.

As of 2013, co-founder Max Wicha was the director of the University of Michigan Comprehensive Cancer Center and remained a consultant to OncoMed, while co-founder Michael Clarke had taken up a position at Stanford University.

In 2013, OncoMed had at least two direct competitors, both public American companies: Stemline Therapeutics and Verastem. By 2014, the list of firms pursuing therapies targeting cancer stem cells had grown to include Boston Biomedical (a subsidiary of Dainippon Sumitomo Pharma), GlaxoSmithKline, Astellas Pharma, Sanofi (the American subsidiary) and Pfizer; however, Stemline and Verastem remain the only two competitors solely focused on cancer stem cells. One analyst holds that OncoMed is the best positioned of the three companies focused on the cancer stem cell area.

As of January 2017, Oncomed had seven clinical-stage drugs in development and four discovery-stage investigations; no OncoMed therapies have made it to market yet. Two candidate drugs being co-developed with Bayer, ipafricept and vantictumab, showed in mid-2014 indications of "causing mild-to-moderate bone-related side effects" among Phase I clinical trial participants, an observation which led the company to halt enrollment and dosing in the trials, and which contributed to a sharp decline in share price.

Demcizumab, OMP-305B83, and OMP-131R10 are being developed in collaboration with Celgene. Tarextumab and brontictuzumab are being developed in collaboration with GlaxoSmithKline Vantictumab and ipafricept are being developed in collaboration with Bayer.

As of 2013, OncoMed's chief executive officer (CEO) was Paul Hastings, who took the post in 2006. As of 2007, the company's head of R&D was John Lewicki, and the director of operations was Chuck Alaimo.

While serving as OncoMed's CEO, Hastings was also a member of the board of directors for the California Healthcare Institute and the Bay Area Biosciences Association, as well as chairing the board of the Biotechnology Industry Organization. Hastings education includes a bachelor's degree in pharmacy from the University of Rhode Island.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS

Ratings

2016-06-08 Reiterated Rating Cantor Fitzgerald Buy
2016-06-01 Lower Price Target Mizuho Neutral $45.00 to $40.00
2016-05-26 Boost Price Target Mizuho Buy $15.00 to $16.00
2016-05-22 Reiterated Rating Jefferies Group Buy
2016-05-06 Reiterated Rating Jefferies Group Buy $16.00 to $15.00
2016-05-06 Reiterated Rating Cantor Fitzgerald Buy $16.00
2016-05-05 Boost Price Target Leerink Swann Market Perform $11.00 to $13.00
2016-04-18 Initiated Coverage Cantor Fitzgerald Buy $16.00
2016-04-11 Initiated Coverage BMO Capital Markets Outperform $20.00
2016-03-09 Lower Price Target JMP Securities Market Outperform $21.00 to $18.00
2016-01-26 Lower Price Target Mizuho Buy $40.00 to $15.00
2016-01-25 Downgrade Leerink Swann Outperform to Market Perform $27.00 to $11.00
2016-01-06 Lower Price Target Mizuho Neutral $45.00 to $40.00
2015-12-03 Initiated Coverage Wells Fargo Outperform
2015-12-03 Initiated Coverage Wells Fargo & Co. Outperform
2015-11-05 Reiterated Rating Leerink Swann Outperform
2015-10-15 Lower Price Target Jefferies Group Buy $32.00 to $28.00
2015-09-28 Reiterated Rating Jefferies Group Buy $32.00
2015-09-08 Initiated Coverage Jefferies Group Buy $32.00
2015-06-02 Set Price Target Piper Jaffray Buy $43.00
2015-06-02 Set Price Target Piper Jaffray Cos. Buy $43.00
2015-05-04 Set Price Target BMO Capital Markets Buy $43.00
2014-11-19 Reiterated Rating BMO Capital Markets Positive
2014-10-07 Initiated Coverage JMP Securities Outperform $28.00
2014-10-07 Initiated Coverage Jefferies Group Market Outperform $28.00
2014-08-28 Reiterated Rating BMO Capital Markets Hold
2014-06-13 Reiterated Rating Mizuho Buy
2014-05-09 Lower Price Target Jefferies Group $50.00 to $48.00
2014-02-11 Initiated Mizuho Buy $45
2014-02-10 Initiated Coverage Mizuho Buy $45.00
2014-01-17 Boost Price Target Piper Jaffray $48.00
2013-12-04 Boost Price Target Jefferies Group Buy $27.00 to $46.00
2016-06-08 Reiterated Rating Cantor Fitzgerald Buy
2016-06-01 Lower Price Target Mizuho Neutral $45.00 to $40.00
2016-05-26 Boost Price Target Mizuho Buy $15.00 to $16.00
2016-05-22 Reiterated Rating Jefferies Group Buy
2016-05-06 Reiterated Rating Jefferies Group Buy $16.00 to $15.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Funds

In OMED 0 funds of 2213 total. Show all

Fund name Ticker shares

Major Shareholders

Name Relationship Total Shares Holding stocks
GLAXOSMITHKLINE PLC 8.76%  (2607546) AGTC / CNCE / FOLD / GNCA / OMED / PATH / TBPH / THRX /
Broderick James W. 8.43%  (2509671) OMED /
MORGENTHALER PARTNERS VII LP 8.43%  (2509671) GBIM / OMED /
Pollard-Knight Denise 6.53%  (1943509) BIOD / IDIX / OMED /
VERTICAL GROUP LP 2.70%  (803694) OMED /
LASERSOHN JACK W 0.62%  (185709) MASI / OMED /
Gould Terry P 0.42%  (125060) CRVS / OMED /
KARSEN PERRY A 0.27%  (80500) AGIO / CELG / NAVB / NTLA / OMED /
Hoey Timothy SVP, Cancer Biology 0.26%  (77225) OMED /
Gurney Austin See Remarks 0.26%  (76766) OMED /
HASTINGS PAUL J President & CEO 0.26%  (76188) OMED / PCRX / PRTO / RLYP /
Patel Sunil SVP & Chief Business Officer 0.23%  (69538) LGND / OMED /
Li Yvonne See Remarks 0.20%  (59890) OMED /
PRESIDIO MANAGEMENT GROUP VIII L L C 0.19%  (56528) ATRC / OMED /
Lewicki John A. EVP & Chief Scientific Officer 0.19%  (55418) OMED /
Hager Alicia J. VP & General Counsel 0.18%  (54596) OMED /
Stagg Robert SVP, Clinical R&D 0.15%  (43283) OMED /
Woody James N. 0.11%  (33703) OMED / TLOG /
LVP GP I, LLC 0.11%  (33703) OMED /
Waddill William D. SVP & Chief Financial Officer 0.10%  (29758) ARWR / CALA / OMED / PTGX /
Dupont Jakob SVP & Chief Medical Officer 0.07%  (20642) OMED /
PAKIANATHAN DEEPIKA 0.06%  (18940) ALDR / ALXA / CALA / KPTI / OMED /
Lasky Laurence 0.03%  (10332) OMED /